{
    "clinical_study": {
        "@rank": "13460", 
        "arm_group": {
            "arm_group_label": "Picosecond Laser System", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Pico laser is effective and safe in the\n      treatment of unwanted tattoos."
        }, 
        "brief_title": "Laser Treatment of Tattoos With Pico Laser", 
        "condition": "Unwanted Tattoos", 
        "detailed_description": {
            "textblock": "The Investigational device is a dual wavelength laser system developed for treatment of\n      pigmented lesions and for tattoo removal. The base unit is a GentleMax Pro laser system\n      modified to emit light at wavelengths of 532 and 1064 nm and deliver pulse energy up to\n      400mJ, and pulse duration of 700 ps.\n\n      A multicenter study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Has Fitzpatrick skin type  I-IV\n\n          2. Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments to remove\n             them\n\n          3. Is willing to consent to participate in the study\n\n          4. Is willing to comply with all requirements of the study including being photographed,\n             following post treatment care and attending all treatment and follow up visits\n\n        Exclusion Criteria:\n\n          1. Is hypersensitive to light exposure\n\n          2. Has an active sun tan\n\n          3. Has Fitzpatrick skin type  V or VI\n\n          4. Has active localized or systemic infection\n\n          5. Is taking medication(s) for which sunlight is a contraindication\n\n          6. Has a history of squamous cell carcinoma or melanoma\n\n          7. Has a history of keloid scarring\n\n          8. Has used oral isotretinoin (Accutane\u00ae) within 12 months of initial treatment or plans\n             on using during the course of the study.  Note: Skin must regain its normal degree of\n             moisture prior to treatment.\n\n          9. Has a history of immunosuppression/immune deficiency disorders (including HIV\n             infection or AIDS) or use of immunosuppressive medications\n\n         10. Is female and pregnant, has been pregnant within the last 3 months, is currently\n             breast feeding or planning a pregnancy during the study period\n\n         11. Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146807", 
            "org_study_id": "IH132801"
        }, 
        "intervention": {
            "arm_group_label": "Picosecond Laser System", 
            "description": "Picosecond Laser System for the Treatment of Unwanted Tattoos", 
            "intervention_name": "GentleMax Pro laser system", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Tattoos, Picosecond Laser, Syneron", 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20005"
                    }, 
                    "name": "Washington Institute of Dermatologic Laser Surgery"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10028"
                    }, 
                    "name": "New York Laser and Skin Care"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ardmore", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19003"
                    }, 
                    "name": "Main Line Center for Laser Surgery"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "LASER TREATMENT OF TATTOOS WITH A DUAL WAVELENGTH PICOSECOND LASER", 
        "other_outcome": {
            "description": "Adverse events will be evaluated immediately after and before each subsequent laser treatment and will be based on the incidence and severity of side effects caused by the laser treatments.", 
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "overall_official": {
            "affiliation": "Syneron Medical Ltd.", 
            "last_name": "Shlomit Mann", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Global percentage of tattoo clearance evaluated by blinded observers using post treatment photographs compared to baseline photographs.", 
            "measure": "Global percentage of tattoo clearance", 
            "safety_issue": "No", 
            "time_frame": "3 months post the final treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146807"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The average number of treatments will be determined in order to obtain 50% and 75% tattoo clearance.  Rate of clearance will be assessed globally independent of tattoo color and based on individual colors.", 
            "measure": "Rate of tattoo clearance", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Syneron Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Syneron Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}